IMD-Pharma raises 840 k€ from private investors (BAs and WiSEED) to accelerate the development of its assets for the treatment of Rheumatoid Arthritis. par IMDPharmaadm | Déc 12, 2021 | Non classé
IMD-Pharma signs a hosting contract with the Inserm research unit U1291 (Infinity, Toulouse). par IMDPharmaadm | Déc 4, 2021 | Non classé